ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy PDF Print E-mail
Monday, 07 June 2010 11:08
ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.

The patent comes nearly two years after it was developed by University of Tennessee Health Science Center researchers Arnold Postlethwaite and Andrew Kang and acquired by ArGentis. ArGentis, a Memphis-based specialty biopharmaceutical company, began the patent process and Phase I trials of ARG201 in 2008.

The treatment is for systemic sclerosis, a form of scleroderma, a widespread connective tissue disease that affects the skin, blood vessels, muscles and internal organs. The disease affects about 100,000 people in the U.S. If ARG201 proves successful through its trial, it would become one of the first therapies for patients who have had the disease between three and 10 years, says Ted Townsend, COO of ArGentis.

“This is an unmet medical need and it would be first in class from a commercialization standpoint,” he says.

Source: Memphis Business Journal
 
More articles :

» Systemic Sclerosis: An Update

Systemic sclerosis (SSc) is a clinically heterogeneous, systemic disorder affecting connective tissue of skin, internal organs, and walls of blood vessels. It is characterized by alterations of the microvasculature in the form of hypoxia, digital...

» The Management and Treatment of Scleroderma is Improving

Management of systemic sclerosis is likely to improve as soon as an ongoing convergence of mechanistic insights, improved understanding of clinical trial design, and interest by industry results in new treatments, according to Dr. Robert F....

» Survival In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc) and one of the leading causes of morbidity and mortality in this disease. Although several recent studies have suggested an improvement in the prognosis of...

» Unite Against Scleroderma

{gallery}unite{/gallery}

» Unite Against Scleroderma Event Scheduled For May 5th, 2013

is a rare, autoimmune, connective tissue disease characterized by the overproduction of collagen, which results in the thickening and hardening of the underlying connective tissues which support the skin, blood vessels, muscles, and internal organs...

» The Pain Perspective in Scleroderma

Systemic sclerosis (scleroderma) is a disease in which inflammatory and fibrotic changes result in overproduction and accumulation of and other extracellular matrix proteins, resulting in intimal vascular damage, fibrosis, and occasionally organ...

Add comment

Do feel free to leave your comments, as they would add value and knowledge to the community. However, please refrain from making any disparaging, uninformed, or unrelated comments. Thanks :)

Security code
Refresh